Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA

Overview

Darolutamide is a drug that has a proven survival benefit in non-metastatic (M0) castrate resistant prostate cancer when using conventional imaging. However, it is estimated that >90% of patients have disease apparent when using PSMA PET. This study investigates the use of local consolidation radiotherapy in this cohort of men.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 2026

Detailed Description

This study explores the use of local consolidation therapy in the setting of Darolutamide in the initial diagnosis of metastatic castrate resistant prostate cancer (mCRPC). In the chemotherapy naïve mCRPC setting, the pattern of disease is of limited volume metastases (1-5) in 34%-40% of cases. As progression at known sites of macroscopic disease is the predominant cause of failure on systemic therapies, local consolidation therapy with stereotactic ablative body radiotherapy (SABR) may improve progression free survival (PFS) and overall survival (OS). This approach has been tested in the setting of lung cancer, in which consolidation SABR has resulted in OS benefit (HR of 0.40) in phase II studies. The novel approach of local consolidation therapy has not been tested as yet in mCRPC. The secondary objective of this study proposal is to better understand the pattern of disease distribution at first diagnosis of CRPC. Previous studies have used conventional bone scan and CT imaging, and with these investigations the proportion of patients that are 'M0' is ~35%1. However, in the new era of PSMA PET, which is far more sensitive than conventional imaging, there exists a new group of men who are M0 on conventional imaging but are M1 on PSMA PET staging. Thus, in the DECREASE study population, we expect the vast majority of patients with conventionally imaged 'M0 CRPC' will have disease detectable on PSMA PET scanning. In this context, the central hypothesis of this trial is that the addition of consolidation radiotherapy to darolutamide to PSMA detected sites of disease will improve the clinical outcome of patients compared to those patients receiving darolutamide alone.

Interventions

  • Drug: Darolutamide
    • Darolutamide alone
  • Radiation: Radiotherapy
    • Darolutamide + Consolidation Radiotherapy

Arms, Groups and Cohorts

  • Experimental: Darolutamide
    • Darolutimide 600mg BD
  • Experimental: Local consolidation Radiotherapy + Darolutamide
    • Darolutimide 600mg BD + local consolidative radiotherapy, with a biological equivalent dose of 30Gy/10fx or greater if delivered with SABR. SABR is the preferred treatment approach, however conventional radiotherapy is acceptable. To up to 5 sites of disease

Clinical Trial Outcome Measures

Primary Measures

  • Undetectable PSA at 12 months
    • Time Frame: 12 months
    • Undetectable PSA at 12 months

Secondary Measures

  • Radiological progression free survival
    • Time Frame: 36 months
    • Radiological progression free survival
  • Distribution of disease on baseline PSMA-PET/CT imaging
    • Time Frame: 36 months
    • Distribution of bone, nodal, visceral and recurrent primary disease on PSMA-PET/CT
  • Biochemical progression free survival
    • Time Frame: 36 months
    • Biochemical progression free survival
  • Treatment related adverse event
    • Time Frame: 36 months
    • Treatment related adverse events (CTCAE v 5.0)
  • Overall survival
    • Time Frame: 36 months
    • Overall survival
  • Patterns of disease on PSMA PET/CT after 12 weeks of commencing Darolutamide, and at time of disease progression
    • Time Frame: 3 months
    • PSMA avid disease at irradiated site / unirradiated site / bone / local / nodal / visceral

Participating in This Clinical Trial

Inclusion Criteria

  • ≥ 18 years of age and provided written Informed Consent – Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features – Castration-resistant prostate cancer, defined as at least 2 consecutive PSA rises obtained at least 1 week apart in the setting of castrate testosterone levels – Castrate level of serum testosterone (<1.7 nmol/l [50 ng/dl]) on gonadotrophin - releasing hormone (GnRH) agonist or antagonist therapy or after bilateral orchiectomy – A baseline PSA level of at least 1ng per millilitre and a PSA doubling time of 10 months or less – Adequate bone marrow reserve and organ function Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 – At least 1 site of PSMA-avid disease on PSMA-PET/CT imaging in any of the following regions; At least 1 site of PSMA-avid disease on PSMA-PET/CT imaging in any of the following regions: – Local recurrence within the prostate gland or prostate bed – Regional lymph node disease (below the aortic bifurcation) – Extra-pelvic lymph node, bone or soft tissue metastatic disease Exclusion Criteria:

  • Patients with detectable metastases or a history of metastatic disease on conventional imaging – Prior treatment with second-generation androgen receptor (AR) antagonists, CYP17 enzyme inhibitors or oral ketoconazole – Use of oestrogens or 5-α reductase inhibitors or anti-androgens within 28 days before randomisation – Use of systemic corticosteroid with a dose greater than the equivalent 10 mg of prednisone/day within 28 days before randomisation – Radiotherapy within 12 weeks prior to randomisation – Initiation of treatment with an osteoclast-targeted therapy to prevent skeletal-related events within 12 weeks before randomisation – Any of the following within 6 months before randomisation: stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft; congestive heart failure New York Heart Association (NYHA) Class III or IV – Uncontrolled hypertension – Prior malignancy – Gastrointestinal disorder or procedure that expects to interfere significantly with the absorption of study treatment – Unable to swallow study medications and comply with study requirements

Gender Eligibility: Male

Castration-resistant prostate cancer

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Trans Tasman Radiation Oncology Group
  • Collaborator
    • Bayer
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Shankar Siva, Study Chair, Peter MacCallum Cancer Centre, Australia
    • Arun Azad, Study Chair, Peter MacCallum Cancer Centre, Australia
  • Overall Contact(s)
    • Rebecca Montgomery, +61 2 4014 3910, decrease@trog.com.au

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.